Opendata, web and dolomites

transMed SIGNED

Educating the next generation of scientists in translational medicine: Focus on eye diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 transMed project word cloud

Explore the words cloud of the transMed project. It provides you a very rough idea of what is the project "transMed" about.

intellectual    employability    biomedical    property    hctc    wealth    innovative    therapies    models    disease    opportunity    phd    drug    lectures    translation    industry    rds    altogether    clinical    transmed    toxicological    data    sppd    degenerations    vice    stages    untreatable    bedside    networking    incu    biotech    pamgene    inclusion    evi    broadest    affairs    translational    joins    intersectoral    good    groups    rd    delays    ulund    regulatory    hands    basic    conferences    degree    curriculum    builds    proposes    integrates    definition    medicine    unimore    successful    private    expertise    stage    sme    biomarkers    bench    mechanisms    permitting    competitive    oculis    training    retinal    biolog    academia    urgently    versa    treatments    commercialisation    course    ekut    secondment    manufacturing    vitro    overview    pharmacokinetics    critical    respectively    ongoing    young    educate    collaborations    experiences    academic    2bbb    gap    obtain    public    hi    blinding    trials    students    nlo    establishment    vivo   

Project "transMed" data sheet

The following table provides information about the project.

Coordinator
EBERHARD KARLS UNIVERSITAET TUEBINGEN 

Organization address
address: GESCHWISTER-SCHOLL-PLATZ
city: TUEBINGEN
postcode: 72074
website: www.uni-tuebingen.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 3˙327˙702 €
 EC max contribution 3˙327˙702 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2017
 Funding Scheme MSCA-ITN-ETN
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2021-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EBERHARD KARLS UNIVERSITAET TUEBINGEN DE (TUEBINGEN) coordinator 498˙432.00
2    HASKOLI ISLANDS IS (REYKJAVIK) participant 538˙290.00
3    LUNDS UNIVERSITET SE (LUND) participant 527˙318.00
4    RISE RESEARCH INSTITUTES OF SWEDEN AB SE (BORAS) participant 527˙318.00
5    UNIVERSITA DEGLI STUDI DI MODENA E REGGIO EMILIA IT (MODENA) participant 516˙122.00
6    INOCURE SRO CZ (PRAHA) participant 464˙844.00
7    PAMGENE INTERNATIONAL BV NL (DEN HAAG) participant 255˙374.00
8    OCULIS EHF IS (REYKJAVIK) participant 0.00
9    SP PROCESS DEVELOPMENT AB SE (BORAS) participant 0.00
10    2-BBB MEDICINES BV NL (LEIDEN) partner 0.00
11    BIOLOG LIFE SCIENCE INSTITUTE, FORSCHUNGSLABOR UND BIOCHEMICA- VERTRIEB GMBH DE (BREMEN) partner 0.00
12    European Vision Institute EEIG BE (BRUXELLES) partner 0.00
13    HANNOVER CLINICAL TRIAL CENTER GMBH DE (HANNOVER) partner 0.00
14    NLO European Patent and Trademark NL (Amsterdam) partner 0.00

Map

 Project objective

Medicine today experiences a gap between basic research and successful clinical translation that delays establishment of urgently needed therapies. This is very clearly so in blinding retinal degenerations (RDs), where most are yet untreatable, even with a wealth of basic and pre-clinical research data available. To address this problem, transMed proposes an innovative programme to educate “translational researchers” that focuses on the bench-to-bedside development of treatments for RD.

The transMed consortium joins four academic groups (EKUT, UNIMORE, ULUND, HI) with four non-academic and SME partners (SPPD, INCU, Oculis, PamGene), and five partner organisations (2BBB, BIOLOG, NLO, HCTC, EVI) with intersectoral collaborations already ongoing. Each transMed partner will contribute specific critical expertise to a curriculum covering all major aspects of translational research: From basic research into disease mechanisms and target definition, to drug design and development, in vitro test systems and in vivo disease models, drug delivery systems, biomarkers, good manufacturing practice, toxicological testing and pharmacokinetics, regulatory affairs, intellectual property, all the way to clinical trials and commercialisation.

transMed builds on and integrates three relevant translational projects, which are at the early pre-clinical, late pre-clinical, and early clinical stages, respectively, to provide the project’s Early Stage Researchers with the broadest possible overview. The training is completed by e-lectures, the inclusion of dedicated conferences for young researchers, a secondment and hands-on course programme from industry to academia and vice versa, permitting further insight and networking in the European biotech industry. Altogether, transMed will offer its students the opportunity to obtain a competitive PhD degree in several critical areas of biomedical research, providing for a strong employability in both the private and public sector.

 Deliverables

List of deliverables.
Communication and dissemination I Documents, reports 2020-04-16 14:24:21
Dissemination material Documents, reports 2020-04-16 14:24:16
Project website Websites, patent fillings, videos etc. 2020-04-16 14:24:12

Take a look to the deliverables list in detail:  detailed list of transMed deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Erico Himawan, Per Ekström, Matej Buzgo, Pieter Gaillard, Einar Stefánsson, Valeria Marigo, Thorsteinn Loftsson, François Paquet-Durand
Drug delivery to retinal photoreceptors
published pages: 1637-1643, ISSN: 1359-6446, DOI: 10.1016/j.drudis.2019.03.004
Drug Discovery Today 24/8 2020-02-04
2019 Arianna Tolone, Soumaya Belhadj, Andreas Rentsch, Frank Schwede, François Paquet-Durand
The cGMP Pathway and Inherited Photoreceptor Degeneration: Targets, Compounds, and Biomarkers
published pages: 453, ISSN: 2073-4425, DOI: 10.3390/genes10060453
Genes 10/6 2020-02-04

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRANSMED" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TRANSMED" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

i-CONN (2019)

Interdisciplinary connectivity: Understanding and managing complex systems using connectivity science

Read More  

BIGMATH (2018)

Big Data Challenges for Mathematics

Read More  

FEINART (2020)

The Future of European Independent Art Spaces in a Period of Socially Engaged Art

Read More